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Received September 11, 2012; accepted May 3, 2013AbstractBackground: Increasing evidence suggests that innate immunity is involved in the development of nonalcoholic fatty liver disease. Nod-like receptors
(NLRs) have recently been identified as key mediators of inflammatory and immune responses. The aim of this article is to explore the correlation of
nucleotide-binding oligomerization domain (NOD)-like receptor (NLR)X1 and NLRP3 with nonalcoholic steatohepatitis (NASH) in mice.
Methods: In our study, a high-fat diet, lipopolysaccharides (LPSs), and normal diet were given to C57BL mice to establish high fat (HF),
HF þ LPS, and control groups. Thereafter, serum alanine and aspartate aminotransferase (ALT and AST) levels were measured, and NASH
severity was histologically examined. We measured tumor necrosis factor (TNF)-a levels by enzyme-linked immunosorbent assay, protein
expression by Western blotting, and mRNA expression by real-time fluorescent quantitative reverse transcription-polymerase chain reaction.
Results: Levels of ALT and ASTwere higher in HF þ LPS mice than in HF mice ( p < 0.05). NLRX1 mRNA and protein expression was lower
in HF and HF þ LPS mice than in control mice (r < 0.05). NLRP3 mRNA expression was higher in HF and HF þ LPS mice than in control
mice (r < 0.05). The mRNA and protein expression of TNF receptor-associated factor (TRAF)6, interleukin-1b, caspase-1, and apoptosis-
associated speck-like protein were significantly higher in HF þ LPS mice than in control and HF mice; furthermore, mRNA expression was
higher in HF mice than in control mice (r < 0.05), but protein expression was similar.
Conclusion: NLRX1 and NLRP3 inflammasomes may be important in NASH development.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: C57BL mouse; NLRP3; NLRX1; nonalcoholic steatohepatitis1. Introduction
Nonalcoholic fatty liver disease (NAFLD) affects 10e24%
of the general population in various countries and is therefore
an important public health problem.1 Chronic, low-grade,
systemic inflammatory responses have been associated with
obesity and insulin resistance (IR), and increased levels of
inflammatory cytokines can impair insulin action via antago-
nistic signals,2 thereby facilitating the onset and development
of nonalcoholic steatohepatitis (NASH). In recent years, great
advances have been made in our understanding of the function* Corresponding author. Dr. Min Shi, Department of Gastroenterology,
Shanghai Changning Central Hospital, Xianxia Road, Number 1111,
Changning District, Shanghai 200336, China.
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1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.08.010and mechanism of innate immune responses in pathological
processes such as autoimmune diseases, bacteria-free inflam-
mation, and chronic inflammatory response. In particular, the
pattern recognition mechanism and downstream regulatory
networks of nucleotide-binding oligomerization domain
(NOD)-like receptors (NLRs) have attracted considerable
attention. NLRs form a cytoplasmic protein family and were
recently discovered to play a role in inflammatory responses;
these molecules include important innate immune system re-
ceptors [e.g., Toll-like receptors (TLRs)] that form a defense
against pathogens. NLRs actively participate in pathogen-
associated molecular patterns and detect danger-associated
molecular patterns, thus enabling relevant inflammatory
responses.
NLRX1, a member of the NLR family, has been recently
found to bind to tumor necrosis factor (TNF) receptor-hinese Medical Association. All rights reserved.
Table 1
Primer probe sequences.
mRNA Sequence (50e30)
NLRP3 F: TATCAAGCCCTCCTTCACCATC
R: CCTCTGGCAGTTTCACGTTATC
ASC F: GCTCTGCCTCCTGAGTTATG
R: TGCCCTCTTCTGGCTTTG
Caspase-1 F: CGTCTTGCCCTCATTATC
R: CACCTCTTTCACCATCTC
NLRX1 F: GGGTTGCAACTCAACAATCT
R: TGTTGGAGAGCCTAAGAGTG
TRAF6 F: TCCAGGGACTGGTTTAACCC
R: GCCGCCTGGAGCATATTTCA
IL-1b F: TAGGCTCATCTGGGATCCTC
R: AAAAGGTGGCATTTCACAGT
b-Actin F: GTCGTACCACTGGCATTGTG
R: GCTGTGGTGGTGAAGCTGTA
ASC ¼ apoptosis-associated speck-like protein; IL-1b ¼ interleukin-1b;
NLRX1 ¼ nucleotide-binding oligomerization domain (NOD)-like receptor
X1; TRAF6 ¼ tumor necrosis factor (TNF) receptor-associated factor-6.
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factor-kappaB (NF-kB) pathway, thus acting as a negative
regulator of excessive inflammatory responses.3 NLRP3,
another typical representative of the NLR family, is a
macromolecular protein complex with a molecular weight of
700 kDa; NLRP3 along with apoptosis-associated speck-like
protein (ASC) and caspase-1 constitute NLRP3 inflamma-
somes. These function as receptors of exogenous microor-
ganisms or endogenous danger signals in the cytoplasm.
Activation of NLRP3 inflammasomes can regulate the matu-
ration and secretion of proinflammatory cytokines, including
interleukin (IL)-1b, IL-18, and IL-33.4
Chitturi and Farrell5 reported that 98% of NAFLD patients
had associated IR, which is an important element in the
development of NASH. Inflammatory factors such as NF-kB,
IL-1b, and IL-18 are closely related to IR, and the activation
of these factors is regulated by NLRX1 and NLRP3. There-
fore, we hypothesized that NLRX1 and NLRP3 inflamma-
somes are involved in the onset and development of NASH. To
verify this hypothesis, we established a mouse model of
NASH to investigate the correlation of NLRX1 and NLRP3
with NAFLD.2. Methods2.1. AnimalsFifteen specific-pathogen-free male C57BL6 mice 4 weeks
of age and weighing 12e16 g were purchased from the
Shanghai Laboratory Animal Center, Chinese Academy of
Sciences (Shanghai, China). The mice were fed in a clean-
grade barrier systems laboratory in the Laboratory Animal
Centre, with the Shanghai Jiao Tong University College of
Medicine. All experiments with animals were performed
according to the guidelines of the Ethical Committee in China.
All studies were performed with the approval of the Experi-
mental Animal Committee of Shanghai Changning Central
Hospital, Shanghai, China.2.2. ReagentsWe bought lipopolysaccharide (LPS) from Sigma-Aldrich
(St. Louis, MO, USA); NLRP3, caspase-1, ASC, and b-actin
antibodies from Santa Cruz Biotechnology (Santa Cruz, CA,
USA); NLRX1 and TRAF6 antibodies from Abcam (Cam-
bridge, UK); Trizol from Invitrogen (Carlsbad, CA, USA);
polymerase chain reaction (PCR) mix kit and primer probe
sequences from Daweike Biotechnology Co. Ltd. (Shanghai,
China; Table 1); enzyme-linked immunosorbent assay
(ELISA) kit and immunohistochemistry (IHC) primary anti-
IL-6 antibody from Perseus Proteomics Inc. (Tokyo, Japan);
secondary antibody kit [Elivision plus polymer horseradish
peroxidase (Mouse/Rabbit) IHC kit] and 4-
dimethylaminoazobenzene (DAB) chromogenic agent from
Maixin Biology Co. Ltd. (Fuzhou, China); and a real-time
fluorescent quantitative PCR device (7500 SequenceDetection System) from Applied Biosystems Inc. (Foster City,
CA, USA).2.3. Animal model and groupsThe experimental animals were randomly assigned to three
groups of five mice each: control group, HF (high-fat diet)
group, and HF þ LPS (high-fat diet þ intraperitoneal LPS
injections) group. The control group mice were fed a normal
diet, and the HF and HF þ LPS group mice were fed an HF
diet for 12 weeks. In Week 12, the HF þ LPS group mice were
intraperitoneally injected with 10 mg/kg LPS. At the end of
12 weeks, all mice were sacrificed by cervical spine damage
12 hours after fasting. Thereafter, 1 mL blood was extracted
from their eyeballs, and their liver tissues were quickly har-
vested. The harvested tissues were gently flushed with normal
saline in an ice bath and partially fixed with 10% formalde-
hyde solution; a part of the tissues was rapidly stored at
70 C.2.4. Biochemical assaysThe obtained blood was sent to the hospital laboratory for
determination of alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels. The liver tissues were
embedded in paraffin after being fixed in formaldehyde for
24 hours and cut into 4-mm slices for hematoxylin and eosin
(H&E) staining and immunohistochemical staining or stored
under cryogenic conditions for Western blot and PCR
examination.2.5. DietNormal diet was provided by the Basic Medical School
Animal Center, which is affiliated with the Shanghai Jiao Tong
University School of Medicine. The HF diet (50% fats from
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purchased from Slack Company (Shanghai, China).2.6. Histological examinationLiver tissue samples were taken from the same position for
H&E staining, fixed with 10% formaldehyde, paraffin-
embedded, H&E stained, and observed under a microscope.
Hepatic steatosis was classified into the following, depending
on the histological appearance of the tissue samples under a
low-power lens: mild, cells with hepatic steatosis accounted
for 1/3 of hepatic lobules; moderate, cells with hepatic stea-
tosis accounted for 1/3e2/3 of hepatic lobules; and severe,
cells with hepatic steatosis accounted for more than 2/3 of
hepatic lobules.2.7. Real-time PCRWe determined the mRNA expression levels of NLRX1,
TRAF6, IL-1b, NLRP3, caspase-1, and ASC by using real-
time fluorescent quantitative PCR. Total RNA was extracted
using Trizol, the purity and concentration of which were
determined with an ultraviolet spectrophotometer. Reverse
transcription was used to convert 2 mg total RNA to cDNA.
The SYBR Green I dye method was applied. The reverse
transcription products were subjected to amplification of the
b-actin, NLRX1, TRAF6, IL-1b, NLRP3, caspase-1, and ASC
genes. The mRNA expression levels and gray levels in all
groups were compared using an automatic gel-imaging anal-
ysis system after gel electrophoresis of the PCR products. All
results were normalized using the results for b-actin. The
primer sequences and fragments are shown in Table 1. PCR
was performed under the following conditions: initial dena-
turation at 50C for 2 minutes, followed by 40 cycles of
denaturation at 95C for 15 seconds, annealing at 60C for
45 seconds, and elongation at 72C for 30 seconds. b-Actin
was used as an internal reference and was subjected to an
initial denaturation at 94C for 3 minutes, followed by 35
cycles of denaturation at 95C for 20 seconds, annealing at
60C for 20 seconds, and elongation at 72C for 30 seconds; a
repeat elongation was performed at 72C for 10 minutes, with
a final cycle at 4C. Relative mRNA expression was calculated
using the formula relative level ¼ 2  Dct  100%.2.8. Western blot analysisThe protein expression levels of NLRX1, TRAF6, NLRP3,
caspase-1, and ASC were determined with Western blotting.
Liver tissues were refrigerated at 80C immediately after
being harvested, and histone extracts were prepared using
conventional homogenization and centrifugation. The protein
concentration was determined using the BCA protein quanti-
tative kit (SunBio Biomedical Technology Co. Ltd., Beijing,
China), according to the manufacturer’s instructions. Each
histone sample (50 mg loading sample) was denaturated and
then subjected to reducing sodium dodecyl sulfate poly-
acrylamide gel electrophoresis, with 8% polyacrylamide gels.We used a concentrated gel electrophoresis voltage of 80 V
and a separating gel electrophoresis voltage of 120 V. Elec-
trophoresis was performed with bromophenol blue until the
gel bottom was visible; a semidry transmembrane (poly-
vinylidene difluoride membrane) was subjected to a constant
current of 50 mA for 90 minutes. The membrane was sealed
with 5% skim milk powder prepared using Tris-buffered saline
with Tween 20 (TBST) at room temperature for 1 hour. Next,
primary antibodies were added to the membrane, which was
then kept overnight in a table concentrator at 4C. Secondary
antibodies (1:3000) were added after the membrane was
washed with TBST in the table concentrator. The membrane
was incubated at room temperature for 1 hour, repeatedly
flushed with TBST, and subjected to DAB coloration (using a
DAB chromogenic agent kit, in which the reaction was
terminated with water). In a dark room, the nitrocellulose
membrane was brought into full contact with an illuminant
and exposed using X-rays. The films were developed and fixed
with conventional methods. The b-actin expression level of
each membrane was determined and used as an internal
standard.2.9. ELISALiver tissue (1 g) was added to phosphate-buffered saline and
0.1 mmol/L phenylmethylsulfonyl fluoride, adequately grinded
in a homogenizer, and centrifuged at 4C at 100,000 rpm for
15 minutes. The supernatant was subjected to double antibody-
sandwich ELISA and ELISA was performed according to the
manufacturer’s instructions.2.10. Statistical analysisStatistical analysis was performed SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). Variables are expressed as
X  S. Single factors were assessed using analysis of variance,
and groups were compared using the least significant differ-
ence and StudenteNewmaneKeuls method. All statistical
tests were two-sided probability tests (a ¼ 0.05). Differences
were considered statistically significant at p < 0.05.
3. Results3.1. Biochemical assaysSerum ALT levels were significantly higher in the HF and
HF þ LPS groups than in the control group (p < 0.05;
Fig. 1A). The serum AST level did not significantly differ
between the HF and control groups, but was significantly
greater in the HF þ LPS group than in the control group
(p < 0.01; Fig. 1B).3.2. Histological examinationThe samples from the control group showed clear lobular
structure, no inflammatory cell infiltration of the portal area,
and no proliferation of collagen fibers. The HF group showed
Fig. 1. (A) Serum alanine aminotransferase (ALT) and (B) aspartate aminotransferase (AST) levels in HF þ LPS, high-fat diet (HF), and control groups. *p < 0.05,
compared to the control group.
Fig. 2. Histopathological changes in mouse liver on hematoxylin and eosin staining (200). (A) Control group, (B) HF group, and (C) HF þ LPS group.
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collagen fiber proliferation in the portal area. The HF þ LPS
group showed sever liver cell steatosis with numerous in-
flammatory cells infiltrating the portal area. These changes
were indicative of NASH (Fig. 2).3.3. ELISACompared to the control group, the HF and HF þ LPS
groups had significantly greater TNF-a levels ( p < 0.05;
Fig. 3).3.4. Real-time PCRFig. 3. Hepatic tumor necrosis factor-a (TNF-a) levels measured using
enzyme-linked immunosorbent assay (ELISA). *p < 0.05, compared to the
control group. HF ¼ high-fat diet; HF þ LPS ¼ high-fat diet þ intraperitoneal
LPS injections.NLRX1 mRNA expression was lower in the HF and
HFþ LPS groups than in the control group (p< 0.01), whereas
NLRP3 mRNA expression was higher in the HF and HFþ LPS
groups than in the control group (p < 0.05). The expression
levels of TRAF6, IL-1b, caspase-1, and ASC mRNA in the
NASH group were much higher than those in the control and HF
groups (p < 0.01), and the expression levels in the HF group
were higher than those in the control group (p < 0.05; Fig. 4).
Hepatic steatosis progressively worsened with time and even-
tually devolved into steatohepatitis. This pathological process
was associated with a significant increase in TRAF6, IL-1b,
NLRP3, caspase-1, and ASCmRNA expression and an obvious
decrease in NLRX1 mRNA expression.3.5. Western blottingNLRX1 expression levels were lower (p < 0.05; Fig. 5) in
the HF and HF þ LPS groups than in the control group.
TRAF6, NLRP3, caspase-1, and ASC protein expression in the
HF þ LPS group was considerably higher than that in the
control group (p < 0.01) and the HF group (p < 0.05); how-
ever, the expression in the HF group did not differ from that in
the control group (p > 0.05). In HF þ LPS models, the protein
expression levels of NLRP3, caspase-1, and ASC increase and
Fig. 4. Hepatic expression levels of NLRP3, caspase-1, and apoptosis-associated speck-like protein (ASC) mRNA assessed using fluorescent quantitative poly-
merase chain reaction (PCR). *p < 0.05, compared to the control group; **p < 0.01, compared to the control and high-fat diet (HF) groups. IL-1b ¼ interleukin-
1b; NLRX1 ¼ nucleotide-binding oligomerization domain (NOD-like receptor X1; TRAF6 ¼ tumor necrosis factor (TNF) receptor-associated factor-6).
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group when the hepatic steatosis deteriorates to steatohepatitis.
4. Discussion
With the recent increase in the incidence of NASH, this
condition has become the most important cause of cryptogenic
cirrhosis.6 The pathogenesis of NASH is complex and involves
the interaction of genetic predisposition with multiple meta-
bolic disorders. Although the pathophysiological basis of
NASH is known to be IR and oxidative stress, a satisfactoryFig. 5. NLRP3, caspase-1, and apoptosis-associated speck-like protein (ASC) pro
Control group, (B) HF group, and (C) HF þ LPS group. *p < 0.05, compared to the
internal reference. IL-1b ¼ interleukin-1b; NLRX1 ¼ nucleotide-binding oligomeri
receptor-associated factor-6.theory that explains all the clinical phenomena of NASH has
yet to be found.7 Hepatic steatosis and the associated IR are
now widely believed to be major factors in the development of
fatty liver diseases.8 Therefore, all factors that affect IR may
be indispensable to the development of NAFLD. Intraperito-
neal LPS injections are used to promote inflammatory re-
sponses in order to successfully establish liver-damage models
with typical pathological features of NASH, such as significant
ALT elevation.9 These models show ALT levels that are
twice the normal value, moderate-to-severe steatosis, visible
inflammatory infiltration of hepatic lobules, and partialtein expression assessed using Western blotting of mouse liver samples. (A)
HF group, **p < 0.01, compared to the control group. b-Actin was used as an
zation domain (NOD)-like receptor X1; TRAF6 ¼ tumor necrosis factor (TNF)
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indicate successful establishment of the NASH model. The
experimental findings are similar to Ma et al’s10 research.
They used an animal model of a diet-induced fatty liver: mice
fed a high-fat diet develop obesity, steatosis, and IR similar to
those seen in humans. Under normal, pathogen-free condi-
tions, HF-fed mice do not develop spontaneous steatohepatitis.
However, these mice are unusually susceptible to a small dose
of exogenous LPS and develop liver inflammation when
exposed to LPS.10 IR and inflammatory responses, the major
pathological changes in NASH,11 modulate NF-kB-dependent
signaling pathways through a number of cytokines such as
TNF and IL-6.12 Because adipose tissue is the main source of
cytokines, hepatic steatosis may promote macrophage infil-
tration and thereby promote the release of numerous cytokines
with potent proinflammatory action, which further aggravates
IR.13 Our results conform to the above theory: TNF-a and NF-
kB p65 protein expression levels were higher in the HF and
HF þ LPS groups than in the control group.14 The NLR family
and its polyproteolytic complexes (inflammasomes),15 as re-
ceptors of the innate immune system, can detect various
danger signals and regulate inflammatory responses by
inducing cell activation and releasing cytokines and inflam-
matory mediators. Thus far, 23 protein molecules belonging to
the NLR family have been found in humans, and 35 molecules
have been found in mice.16
NLRP3, a member of the NLR family, can attract ASC at
the N-terminal pyrin domain (PYD) and attract pro-caspase-1
via ASC to form NLRP3 inflammasomes. These inflamma-
somes play an important role in noninfectious inflammatory
diseases. Preliminary results have indicated that NLRP3
inflammasomes are involved in the onset and development of
acute and chronic noninfectious inflammatory diseases such as
type 2 diabetes, gout, and some kidney diseases.17e20 Ligands
of NLRP3 inflammasomes, including microbes, microbial
toxins, and intracellular danger signals, trigger different
inflammasome activation mechanisms. Thus far, three activa-
tion mechanisms have been discovered: outflow of potassium
ions, lysosomal rupture due to ligands, and generation of
ligand-mediated reactive oxygen species (ROS).16,21 NLRP3
inflammasomes precisely regulate caspase-1 activation, which
is a crucial step in the production and secretion of important
proinflammatory cytokines such as IL-1b, IL-18, and IL-33.22
IL-1b can induce its own expression as well as the expression
of other proinflammatory cytokines, adhesion molecules, and
chemokines such as IL-6, IL-8, and TNF-a. Pro-IL-1b syn-
thesized from inactive precursors must undergo caspase-1-
mediated digestion to form biologically active mature IL-
1b.23 Studies have shown that NLRP3 inflammasomes regu-
late the activation of IL-1b and IL-18, which are closely
related to IR.24,25 IL-1a and IL-1b gene knockout significantly
inhibited the progression of simple steatosis to steatohepatitis
in a diet-induced, wild-type mouse NASH model; thus, liver
IL-1a and/or IL-1b may be therapeutic targets to inhibit the
progression of simple steatosis to NASH.25 The expression
levels of NLRP3, caspase-1, and ASC mRNA greatly increase
with time, and the corresponding protein expression levels aresignificantly higher in the HF þ LPS group than in the HF and
control groups when hepatic steatosis progresses to steatohe-
patitis, indicating that NLRP3 inflammasomes influence
NASH onset and development.
Injection of IL-1 receptor blockers or IL-Trap, a new-
generation IL-1b antagonist,26 can inhibit excessive IL-1b
secretion caused by NLRP3 imbalance, and may thus be used
to treat related genetic or acquired diseases, including
arthritis,27 cryopyrin-related periodic fever syndrome, gout,
and type 2 diabetes.28 This finding suggests that NLRP3
inflammasomes/IL-1b could be used as a new target for
treating NASH. In addition to its involvement in the inflam-
masome signaling pathway, NLRP3 can also activate NF-kB
and induce the classic NF-kB signaling pathway.29 Lamkanfi
et al30 found that caspase-1 can activate NF-kB synchronously
with IL-1b maturation. Negative regulatory mechanisms pre-
vent innate immune responses that seriously damage tissues
and somatic cells. A number of NLR molecules have been
found to be involved in such immune regulation,31 and
NLRX1 is one important member of the family. Recent studies
have shown that NLRXI combined with TRAF6 inhibits the
downstream NF-kB pathway, as a negative regulator of
excessive inflammatory responses.3 NLRX1 is expressed on
the mitochondrial outer membrane. The N-terminal of the
nucleotide-binding domain can combine with the caspase
activation and recruitment domain area of the mitochondrial
antiviral signaling (MAVS) protein.32 Increased cellular
NLRX1 can reduce the activity of the retinoic acid-inducible
gene-1 (RIG-I) and melanoma differentiation-associated
gene-5 (MDA5)-mediated interferon (IFN) pathway. Simi-
larly, NLRX1 inhibition by, for example, vesicular stomatitis
virus infection can increase the levels of type I IFN, but a lack
of the leucin-rich repeat area at the C-terminal of NLRX1C
can lead to a failure of this function.32
Xia et al33 reported that LPS stimulation can rapidly induce
NLRX1 protein ubiquitination, NLRX1 dissociation from
TRAF6, and interaction with inhibitor kB kinase complexes to
ultimately inhibit TLR-triggered NF-kB activation. Allen et al3
reported that NLRX1 not only negatively regulates LPS-induced
TRAF6-mediated activation of the NF-kB signaling pathway,
but also regulates the influenza virus-induced RIG-IeMAVS
pathway, thereby inhibiting the type I IFN-mediated antiviral
immune response. Our results show that NLRX1 mRNA expres-
sion is significantly reduced in steatohepatitis, and thus, NLRX1
protein expression was lower in the HF þ LPS group than in the
HF and control groups. This finding indicates that the onset and
development of NASH is associated with significantly decreased
NLRX1 mRNA and protein expression and inhibition of the
negative regulatory function of NLRX1.
TRAF, a genetically conservative, cytoplasmic signal-
transduction molecule, directly combines with the intracel-
lular domains of cell surface receptors, affecting cell survival,
proliferation, differentiation, and death, and participates in the
regulation of multiple biological processes. TRAF6, as a
regulator of the LPS/TLR4 downstream signaling pathways,
can modulate several signaling pathways [TNF-a, IL-1, and
receptor activator of nuclear factor-kB ligand (RANKL)
692 Y.-G. Wang et al. / Journal of the Chinese Medical Association 76 (2013) 686e692pathways],34 and activate transcription factors such as NF-kB,
activating protein-1, and protein kinase B/Akt, thus mediating
innate/acquired immune and inflammatory responses.35e37 We
found that NLRX1 mRNA and protein expression were
significantly reduced, the negative regulatory function of
NLRX1 was inhibited, and TRAF6 mRNA and protein
expression were significantly increased in the HF þ LPS
group, compared to the HF and control groups. No report has
been found on the correlation of NLRX1 and NLRP3 with
NASH in the existing literature. This experiment indicates that
NLR family members (NLRX1 and NLRP3 inflammasomes)
may be important factors affecting the onset and development
of NASH. This study provided an experimental basis for
further investigation into the role of NLR molecules in NASH.
NLRX1 and NLRP3 inflammasome regulation are potential
new targets of NAFLD treatment, worthy of further study.
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